Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Bluescape Opportunities Acquisition (BOAC.U)
Pine Island Acquisition (PIPP.U)
Gatos Silver, Inc. (GATO)
Biodesix, Inc. (BDSX)
MediaAlpha, Inc. (MAX)
Root, Inc. (ROOT)
Roman DBDR Tech Acquisition (DBDRU)
Ajax I (AJAX.U)
Atlas Crest Investment Corp. (ACICU)
Absolute Software (ABST)
Upcoming IPO
Caliber Home Loans, Inc. (HOMS)
Allegro MicroSystems, Inc. (ALGM)
Mavenir plc (MVNR)
Galecto, Inc. (GLTO)
Leslie's Inc (LESL)
AmeriHome, Inc. (AHM)
OTR Acquisition (OTRAU)
New Beginnings Acquisition (NBA.U)
Lufax Holding Ltd (LU)
Atea Pharmaceuticals, Inc. (AVIR)
SQZ Biotechnologies Company (SQZ)
Priced IPO
Foghorn Therapeutics Inc. (FHTX)
McAfee Corp. (MCFE)
Guild Holdings Company (GHLD)
Abcam plc (ABCM)
Datto Holding Corp. (MSP)
MingZhu Logistics Holdings (YGMZ)
Opthea Limited (OPT)
Eargo, Inc. (EAR)
Aligos Therapeutics, Inc (ALGS)
Praxis Precision Medicines, Inc. (PRAX)
Tarsus Pharmaceuticals, Inc. (TARS)
Array Technologies, Inc. (ARRY)
MINISO Group Holding Limited (MNSO)
Codiak BioSciences, Inc. (CDAK)
Intrusion Securties Inc. (INTZ)
iHuman Inc. (IH)
Shattuck Labs, Inc. (STTK)
Kronos Bio, Inc. (KRON)
Spruce Biosciences, Inc. (SPRB)
Aziyo Biologics, Inc. (AZYO)
More companies

Avidity Biosciences, Inc. (RNA)

Sector - Healthcare

Price chart

Company News

IPO Profile

About company

They are pioneering a new class of oligonucleotide-based therapies called Antibody Oligonucleotide Conjugates (AOCs) designed to overcome the current limitations of oligonucleotide therapies in order to treat a wide range of serious diseases. They utilize their proprietary AOC platform to design, engineer and develop therapeutics that combine the tissue selectivity of monoclonal antibodies (mAbs) and the precision of oligonucleotide therapies in order to access previously undruggable tissue and cell types and more effectively target underlying genetic drivers of diseases. They are initially focused on muscle diseases to demonstrate the capabilities of their AOCs, and their muscle franchise consists of five programs. Their lead product candidate, AOC 1001, is designed to treat myotonic dystrophy type 1 (DM1), a rare monogenic muscle disease. They expect to submit an investigational new drug application (IND) for AOC 1001 in 2021 and plan to initiate a Phase 1/2 clinical trial by the end of the same year. They also intend to advance AOC product candidates in their four other muscle programs focused on the treatment of muscle atrophy, Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease. In addition to their muscle franchise, they have development efforts focused on immune and other cell types.
Industry
PHARMACEUTICAL PREPARATIONS
CEO CFO
Sarah Boyce Michael F. MacLean
Employees Founded
38 2012

Contacts

Address: 10975 N. Torrey Pines Road, Suite 150, La Jolla, CA 92037, US

Telephone: 858-401-7900

Web page: http://www.aviditybiosciences.com

IPO information

Expected Date 6/12/2020
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range $14.00-$16.00
Share prices ($)

Financial Data (last reporting year)

Market Cap (MM) $636.3
Revenues (MM) $3.7
Net Income (Loss) (MM) $-28.3

Voting

What do you think will happen with the RNA share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
Shares Initial (MM) 10
Shares Revised (MM) 14.4
Expected offer amount (MM) $259.2
Realized offer amount(MM) $259.2
Underwriters
Cowen/ SVB Leerink/ Credit Suisse/ Wells Fargo Securities
CO-Managers
-

Sector: Healthcare

Tweets about $RNA

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats